Blake Phillipy’s Post

In a recent independent study, 43% of non-Medtronic‡ SCS patients lost MRI eligibility at 5 years due to out-of-range impedances (1). Medtronic SureScan™ SCS systems are not dependent on impedance, ensuring 100% of SCS patients retain unmatched access† to this important diagnostic tool. See risk information: https://bit.ly/3TG3WIf #MDTPainInterventions #MRI #MRIAccess †Under specific conditions. Refer to product labeling for full list of conditions. ‡Abbott, Boston Scientific, and Nevro (1) Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8

Not all SCS systems are created equal. In fact, a recent independent study found that at five years, 43% of patients with other SCS systems‡ may lose MR eligibility due to impedance conditions. With Medtronic SureScan(TM), 100% of SCS patients still have MRI access† regardless of impedance. (1) View the study: https://lnkd.in/eiaTDE5c #MDTPainInterventions #SCS #MRI #MRIAccess †Under specific conditions. Refer to product labeling for full list of conditions. ‡Abbott, Boston Scientific, and Nevro (1) Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8

Did you know that within five years 43% of non-Medtronic SureScan™ SCS patients‡ may lose MR eligibility due to impedance conditions?(1) With Medtronic SureScan™ systems, patients do not lose MR eligibility due to impedance conditions. Stop by our booth at NANS to learn more about Medtronic's unmatched MRI technology. Join us today for our lunch symposium where industry leaders will review the broad comprehensive pain product portfolio, unmatched MRI access†, and discuss clinical outcomes and data on expanding indications and sensing research. #MDTPainInterventions #MRI #NANS2024 #NANS24 #PatientsFirst ‡Abbott, Boston Scientific, and Nevro (1) Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8

The latest advancement in spinal cord stimulation (SCS) from Abbott | Neuromodulation is here. The Eterna™ SCS System utilizes low-energy BurstDR™ stimulation, which is clinically proven1 to provide superior* pain relief to chronic pain patients. Learn how at https://Eterna.Abbott/EMEA #AbbottProud     Important Safety Info https://bit.ly/isi_int    *BurstDR™ stimulation superiority when compared to traditional tonic stimulation as studied in SUNBURST.  1. Deer T, Slavin KV, Amirdelfan K, et al. Success using neuromodulation with BURST  (SUNBURST) study: results from a prospective, randomized controlled trial using a novel  burst waveform. Neuromodulation. 2018;21(1):56-66. doi:10.1111/ner.12698 

Do you want to take a chance that your patient may lose MR eligibility due to impedance conditions? A recent study showed that is what happened with 43% of non-Medtronic SureScan™ SCS patients† at five years post-implant.(1) With Medtronic SureScan™ systems, 100% of SCS patients have MR access regardless of impedance.‡ Stop by our booth or join us for our lunch symposium where industry leaders, Drs. Chris Beuer, Krishnan Chakravarthy, Samir Sheth, Ricardo Vallejo, and Thomas White, will review the broad comprehensive pain product portfolio, unmatched MRI access§, and discuss clinical outcomes. #MDTPainInterventions #SCS #NANS2024 #NANS24 #MRI #PatientsFirst †Abbott, Boston Scientific, and Nevro ‡ Assuming all other conditions are met § Under specific conditions. Refer to product labeling for full list of conditions. (1) Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8

Gastrointestinal Adverse Effects in GDD. A few words on noncontrast MRI diagnosis. https://wix.to/amOzxvy

We are pleased to announce the publication of a multicenter double-blind randomized, placebo-controlled trial of individuals experiencing moderate-to-severe postoperative pain following knee replacement and treatment with the SPRINT PNS System. The study, published in International Neuromodulation Society's Neuromodulation Journal, highlights the results from the prospective trial evaluating the impact of 60-day peripheral nerve stimulation (PNS) used for chronic knee pain after total knee arthroplasty (TKA). Full story: https://lnkd.in/g375CB6n Cc: David M. Dickerson, MD and Josh Boggs, PhD. Results may vary. Important safety & risk information: https://bit.ly/2FU92NH

Online now in GIE’s Articles in Press: “Top tips for endoscopic therapy for radiation-associated vascular ectasias in the rectum (with video)” by Arvind J. Trindade. Find it at https://lnkd.in/gbkpCKUZ.

The decisions SCS patients make today can have lasting impacts, especially when it comes to MRI access†. Since up to 84% of SCS patients will need an MRI within five years(1), it's vital for healthcare providers to share the most up-to-date data on implant options when receiving informed consent from their patients.  In fact, a new independent study found that at five years post implant, 100% of Medtronic SCS patients still had MRI access†.(2) Learn more: Click here to find resources and learn about SureScan™ MRI technology, go to Medtronic.com/SCSMRI #MDTPainInterventions #SCS #MRI #MRIAccess  (1) Desai MJ, Hargens LM, Breitenfeldt MD, Doth AH, Ryan MP, Gunnarsson C, Safriel Y. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine (Phila Pa 1976). 2015 1;40(9):E531-7. (2) Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8

It is a really hard decision for an IVC or cardiac electrophysiologist to suggest , epicardial LV lead after the failure to deploy it in CS ( obviously due to any technical or anatomical issue) because of the risk involved and the recovery time. even with myopore epicardial lead which is Bi-polar ,it still was not enough ( less vectors) to optimize our CRTs. the recent advances in the Conduction system pacing has revolutionized the idea of physiological pacing. The complete pacing solution 3D with helix locking tool that Abbott has developed solved most of the problem and made it easy and convenient to go for physiological pacing in heart failure patients who are refractory to drug therapy.